Cited 6 times in
ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 박혜지 | - |
dc.contributor.author | 임선민 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 한주연 | - |
dc.date.accessioned | 2017-10-26T07:29:37Z | - |
dc.date.available | 2017-10-26T07:29:37Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152103 | - |
dc.description.abstract | OBJECTIVES: The epidermal growth factor receptor (EGFR) abnormalities including amplification, mutation, and overexpression are frequent in non-small cell lung cancer (NSCLC). We investigated in vitro and in vivo antitumor activity of ER2, a novel human anti-EGFR monoclonal antibody, in NSCLC. METHODS: A panel of NSCLC cell lines (A549, H460, H322, H358, H1299, HCC827, PC9, H1975, and PC9-GR) was used to evaluate in vitro antitumor activity of ER2 and cetuximab. The inhibitory effects of ER2 and cetuximab on downstream signaling were assessed by western blot. Secreted VEGF was measured by Human VEGF Quantikine ELISA kit. Antitumor effects of ER2 and cetuximab as single agents and in combination with cisplatin were evaluated in H322, HCC827 and A549 xenograft models. RESULTS: ER2 efficiently inhibits EGFR and its downstream signaling molecules including Akt and Erk1/2 in NSCLC cell lines with wild-type or mutant EGFR. ER2 inhibited cell viability of H322, HCC827 and A549 cells in a dose-dependent manner by inducing cell cycle arrest and apoptosis. Also, ER2 suppressed EGF-stimulated VEGF production as efficiently as cetuximab in H322, HCC827 and A549 cells. Moreover, ER2 alone and in combination with cisplatin showed a significant anti-tumor efficacy in xenograft mouse models. CONCLUSION: Taken together, ER2 has significant anti-tumor activity in in vitro and in vivo NSCLC models, suggesting a rationale for clinical development of ER2 in NSCLC. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Scientific Publishers | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/pharmacology* | - |
dc.subject.MESH | Antineoplastic Agents/pharmacology* | - |
dc.subject.MESH | Apoptosis/drug effects | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/metabolism* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/pathology* | - |
dc.subject.MESH | Cell Cycle Checkpoints/drug effects | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Cisplatin/pharmacology | - |
dc.subject.MESH | Disease Models, Animal | - |
dc.subject.MESH | Drug Synergism | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy | - |
dc.subject.MESH | Lung Neoplasms/metabolism* | - |
dc.subject.MESH | Lung Neoplasms/pathology* | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Receptor, Epidermal Growth Factor/antagonists & inhibitors* | - |
dc.subject.MESH | Receptor, Epidermal Growth Factor/metabolism | - |
dc.subject.MESH | Signal Transduction/drug effects | - |
dc.subject.MESH | Xenograft Model Antitumor Assays | - |
dc.title | ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models | - |
dc.type | Article | - |
dc.publisher.location | Ireland | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Han Na Kang | - |
dc.contributor.googleauthor | Se-Ho Kim | - |
dc.contributor.googleauthor | Mi Ran Yun | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Sun Min Lim | - |
dc.contributor.googleauthor | Min-Soo Kim | - |
dc.contributor.googleauthor | Kwang-Won Hong | - |
dc.contributor.googleauthor | Sung-Moo Kim | - |
dc.contributor.googleauthor | Hwan Kim | - |
dc.contributor.googleauthor | Kyoung-Ho Pyo | - |
dc.contributor.googleauthor | Hye Ji Park | - |
dc.contributor.googleauthor | Joo Yeun Han | - |
dc.contributor.googleauthor | Hyun A Youn | - |
dc.contributor.googleauthor | Ki-Hwan Chang | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.identifier.doi | 10.1016/j.lungcan.2016.02.013 | - |
dc.contributor.localId | A04945 | - |
dc.contributor.localId | A03369 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04809 | - |
dc.contributor.localId | A05066 | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 27040853 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0169500216302343?via%3Dihub | - |
dc.subject.keyword | Cetuximab | - |
dc.subject.keyword | ER2 | - |
dc.subject.keyword | Epidermal growth factor receptor | - |
dc.subject.keyword | Monoclonal antibody | - |
dc.subject.keyword | Non-small cell lung cancer | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Park, Hye Ji | - |
dc.contributor.alternativeName | Lim, Sun Min | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Pyo, Kyoung Ho | - |
dc.contributor.alternativeName | Han, Joo Yeun | - |
dc.contributor.affiliatedAuthor | Park, Hye Ji | - |
dc.contributor.affiliatedAuthor | Lim, Sun Min | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Han, Joo Yeun | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.citation.volume | 95 | - |
dc.citation.startPage | 57 | - |
dc.citation.endPage | 64 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.95 : 57-64, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 46883 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.